|
|
||||||||
RESEARCH REPORT |
1 Departments of Periodontology and Oral Biology,
2 Biochemistry, and
3 Medicine, Boston University Medical Center, 80 East Concord Street, K-312, Boston, MA 02118;
*corresponding author, btrox{at}bu.edu
| ABSTRACT |
|---|
|
|
|---|
KEY WORDS: protein-protein interactions saliva salivary proteins
| INTRODUCTION |
|---|
|
|
|---|
One of the first applications of random peptide display was to map epitopes of monoclonal antibodies (Philippe et al., 1993; Sibille and Strosberg, 1997; Murthy et al., 1998). A vast number of non-antigen-antibody protein-protein interactions was also identified by this technology (Blond-Elguindi et al., 1993; Koivunen et al., 1994; Pasqualini et al., 1995; Brown et al., 2000; Dintilhac and Bernues, 2002). In addition, display of genetically engineered proteins on cell surfaces has broad application in the field of biotechnology (Samuelson et al., 2002).
Saliva is necessary for the maintenance of oral health, and the unique properties of this fluid are derived in large part from the proteins that are present. In the oral cavity, salivary proteins participate in formation of the acquired enamel pellicle, occur in the biofilm covering oral surfaces, initiate digestion, and promote agglutination and clearance of bacteria (Scannapieco, 1994). Several reports have described heterotypic complexes between salivary proteins, and it has been suggested that such interactions may modulate the function of these molecules in vivo (Rundegren and Arnold, 1987; Biesbrock et al., 1991; Iontcheva et al., 1997).
A bacterial-binding motif exists in the N-terminal region of MG2 (Liu et al., 2000; Soares et al., 2002). This salivary mucin has also been reported to interact with a diverse number of oral microbes (Groenink et al., 1996; Liu et al., 1999, 2000, 2002) and to participate in a heterotypic complex with SIgA (Biesbrock et al., 1991). Together, these properties suggest that MG2 is likely to be an important component of the innate immune system.
| MATERIALS & METHODS |
|---|
|
|
|---|
Test Proteins
A monoclonal antibody directed against human Interleukin 8 (IL-8) was purchased from BIODESIGN (Saco, ME, USA). Salivary mucin MG2 was isolated from human SMSL secretion as described (Liu et al., 1999).
Peptide Display
A peptide display library was purchased from Invitrogen (Carlsbad, CA, USA). This library was comprised of E. coli cells harboring a plasmid (pFlitrx) engineered to express a fusion protein containing random dodecapeptides that were inserted into the active site loop of thioredoxin, which itself was inserted into a dispensable region of flagellin, the major constituent of flagellar filaments. When the fusion protein becomes an integral part of the flagellar filaments on the bacterial cell surface, the dodecapeptides become available to interact with target proteins. The peptide display library was panned 12 times with anti-IL-8 and MG2 according to manufacturers instructions, and resulting libraries were maintained as glycerol stocks. The panning procedure is illustrated in Fig. 1
.
|
Gel Electrophoresis and Blotting
Stimulated SMSL (50 µL) and purified MG2 (3 µg) were examined by SDS-PAGE on 7.5% polyacrylamide gels under denaturing conditions or on pre-cast native 7.5% Tris-HCl gels (BIO-RAD, Hercules, CA, USA) under non-denaturing/non-reducing conditions. Proteins in gels were transferred electrophoretically to nitrocellulose membranes (Protran, Schleicher & Schuell, Keene, NH, USA). The blotting buffer was 0.19 M glycine, 0.025 M Tris-base, pH 8.3, and 20% methanol, and blotting was perfomed at 100 V for 1 hr at room tempertature. Blots were used for Western and Far-Western blotting experiments.
Western Blots
In control experiments suggested by the manufacturer, Western blots of cell extracts from libraries or individual colonies panned with an anti-IL-8 antibody (Lu et al., 1995) were probed with the same antibody. Blots were washed in 10 mM Tris-HCl, pH 7.5, containing 150 mM NaCl and 0.05% Tween 20 (TBST) for 5 min and blocked with 5% milk/TBST at room temperature for 1 hr. Blots were then washed with TBST 3 times for 10 min and incubated with the anti-IL-8 antibody diluted 1:1000 in 1% milk/TBST at room temperature for 1 hr. Blots were washed as above and incubated with goat anti-mouse IgG conjugated to alkaline phosphatase (AP; Promega) diluted 1:5000 in 1% milk/TBST at room temperature for 1 hr. The membrane was washed as above, and color development was obtained by the addition of BCIP (5-bromo-4-chloro-3-indolyl-phosphate) and NBT (nitro blue tetrazolium) according to the manufacturers instructions (Promega). All colonies obtained after 12-time panning reacted with the IL-8 antibody, and sequence analysis showed that selected immunoreactive colonies all contained the IL-8 epitope (data not shown). Western blots of SMSL were probed with our rabbit anti-MG2 antibody directed against a synthetic peptide corresponding to residues 47-63 of secreted MG2 (Liu et al., 1999) diluted 1:1000 or with a rabbit anti-lactoferrin antibody (Jackson Immuno Research, West Grove, PA, USA) diluted 1:5000. The second antibody was goat anti-rabbit IgG conjugated to AP (Jackson Immuno Research) diluted 1:5000. Color development was performed as above.
Far-Western Blots
Blots of SMSL and purified MG2 were washed for 5 min with 10 mM Tris-HCl, pH 7.5, containing 100 mM NaCl and 0.1% Tween-20 (buffer A) and blocked with 5% BSA in buffer A for 1.5 hrs at room temperature. Blots were washed (3x, 10 min) with buffer A, and the membrane was incubated with 50 µg of lactoferrin (Sigma) dissolved in buffer A containing 1% BSA for 5 hrs at 4°C with gentle agitation. After the blots were washed with buffer A (6x, 10 min), immunodetection was performed with the anti-lactoferrin antibody diluted 1:5000 in buffer A containing 1% BSA for 1 hr at room temperature. Blots were washed with buffer A (3 times, 10 min), probed with goat anti-rabbit IgG conjugated to AP diluted 1:5000 in buffer A containing 1% BSA, and washed; color development was with BCIP and NBT.
Periodate Treatment of Glycans
Blots containing SMSL samples were rinsed with 50 mM sodium acetate buffer (pH 4.5) and incubated in the same buffer containing 20 mM periodate for 1 hr at 23°C in the dark (Woodward et al., 1985). Blots were then used to perform Far-Western blots as described above.
Lactoferrin Synthetic Peptide
A peptide (KLADFALLCLDGKRK) corresponding to residues 587-601 of lactoferrin (Swiss-Protein database; accession number ANN 75578) was synthesized commercially (Invitrogen). Blots containing SMSL were blocked and washed (3x, 10 min) with buffer A, and the membrane was incubated with 50 µg of the synthetic peptide-dissolved buffer A containing 1% BSA for 3 hrs at 4°C with gentle agitation. After being washed with buffer A (6x, 10 min), the membrane was incubated with 50 µg of lactoferrin, and immunodetection with anti-lactoferrin antibodies was performed as described above.
| RESULTS |
|---|
|
|
|---|
|
|
|
We synthesized a peptide (KLADFALLCLDGKRK) corresponding to residues 587-601 of lactoferrin and used it to verify the specificity of the interaction between lactoferrin and MG2. This synthetic peptide contained the motif Ala-Leu-Leu-Cys-, identified in panning experiments described above (Table
, clone 8). When membranes were pre-incubated with this peptide prior to being exposed to lactoferrin, the interaction between MG2 and lactoferrin on Far-Western blots was nearly abolished (Fig. 3A
; lanes 9, 10). These results confirm that the motif identified by panning is involved in complexing between MG2 and lactoferrin.
We conducted a parallel series of experiments to determine whether purified MG2 could form a complex with purified lactoferrin and to determine the effects of periodate oxidation and pre-incubation with synthetic peptide on complex formation. The results obtained in these experiments were identical to those described above with MG2 in SMSL (data not shown).
So that we could determine whether MG2 and lactoferrin form a complex in vivo, SMSL was electrophoresed on native gels under non-denaturing conditions, and proteins were transferred to nitrocellulose membranes. When the blot was probed with anti-MG2 antibodies, an immunoreactive band was observed near the top of the gel (Fig. 3B
; lanes 1, 2). When an identical blot was probed with anti-lactoferrin antibodies, two immunoreactive bands were observed (Fig. 3B
; lanes 3, 4). The band near the top of the gel had the same electrophoretic mobility as MG2 and likely represents lactoferrin molecules complexed with MG2. The lower band had the same electrophoretic mobility as standard lactoferrin in this gel system (data not shown). These results suggest that MG2 and lactoferrin form a heterotypic complex in SMSL.
| DISCUSSION |
|---|
|
|
|---|
Analyses of clones interacting with MG2 showed that 4 of 20 dodecapeptides contained a motif suggesting lactoferrin as a potential candidate to complex with MG2. Several experiments confirmed the formation of a heterotypic complex between MG2 and lactoferrin. This is interesting because lactoferrin binds ferric ions and possesses antibacterial, antimycotic, antiviral, antineoplastic, and anti-inflammatory properties (Weinberg, 2001). MG2 interacts with several oral microbes, exhibits candidacidal and bactericidal activity (Liu et al., 2002), is present in the biofilm that covers mucosal surfaces (Collins and Dawes, 1987), has affinity for hydroxyapatite (Tabak et al., 1985), and has been identified in pellicle formed on enamel and cementum (Fisher et al., 1987). Migration of a heterotypic complex between MG2 and lactoferrin to enamel and cementum in gingivitis and periodontal disease could, in principle, result in localization of an antibacterial and an anti-inflamatory protein to sites challenged by oral microbes. The high content of carbohydrate in MG2 could possibly enhance the resistance of lactoferrin to proteolytic attack when complexed to this salivary mucin. Complexing could also modulate removal of these two proteins from the oral cavity, thereby extending the time for them to exert their important biological functions in the oral environment.
| ACKNOWLEDGMENTS |
|---|
Received October 20, 2002; Last revision March 4, 2003; Accepted March 5, 2003
| REFERENCES |
|---|
|
|
|---|
Blond-Elguindi S, Cwirla SE, Dower WJ, Lipshutz RJ, Sprang SR, Sambrook JF, et al. (1993). Affinity panning of a library of peptides displayed on bacteriophages reveals the binding specificity of BiP. Cell 75:717728.[ISI][Medline]
Brown CK, Modzelewski RA, Johnson CS, Wong MK (2000). A novel approach for the identification of unique tumor vasculature binding peptides using an E. coli peptide display library. Ann Surg Oncol 7:743749.[Abstract]
Collins LM, Dawes C (1987). The surface area of the adult human mouth and thickness of the salivary film covering the teeth and oral mucosa. J Dent Res 66:13001302.
Dintilhac A, Bernues J (2002). HMGB1 interacts with many apparently unrelated proteins by recognizing short amino acid sequences. J Biol Chem 277:70217028.
Fisher SJ, Prakobphol A, Kajisa L, Murray PA (1987). External radiolabelling of components of pellicle on human enamel and cementum. Arch Oral Biol 32:509517.[ISI][Medline]
Groenink J, Ligtenberg AJ, Veerman EC, Bolscher JG, Nieuw Amerongen AV (1996). Interaction of the salivary low-molecular-weight mucin (MG2) with Actinobacillus actinomycetemcomitans. Antonie Van Leeuwenhoek 70:7987.[ISI][Medline]
Iontcheva I, Oppenheim FG, Troxler RF (1997). Human salivary mucin MG1 selectively forms heterotypic complexes with amylase, proline-rich proteins, statherin, and histatins. J Dent Res 76:734743.
Iontcheva I, Oppenheim FG, Offner GD, Troxler RF (2000). Molecular mapping of statherin- and histatin-binding domains in human salivary mucin MG1 (MUC5B) by the yeast two-hybrid system. J Dent Res 79:732739.
Jensen JL, Lamkin MS, Oppenheim FG (1992). Adsorption of human salivary proteins to hydroxyapatite: a comparison between whole saliva and glandular salivary secretions. J Dent Res 71:15691576.
Koivunen E, Wang B, Ruoslahti E (1994). Isolation of a highly specific ligand for the alpha 5 beta 1 integrin from a phage display library. J Cell Biol 124:373380.
Liu B, Rayment S, Oppenheim FG, Troxler RF (1999). Isolation of human salivary mucin MG2 by a novel method and characterization of its interactions with oral bacteria. Arch Biochem Biophys 364:286293.[ISI][Medline]
Liu B, Rayment SA, Gyurko C, Oppenheim FG, Offner GD, Troxler RF (2000). The recombinant N-terminal region of human salivary mucin MG2 (MUC7) contains a binding domain for oral Streptococci and exhibits candidacidal activity. Biochem J 345:557564.
Liu B, Rayment SA, Soares RV, Oppenheim FG, Offner GD, Fives-Taylor P, et al. (2002). Interaction of salivary mucin MG2, its recombinant N-terminal region and a synthetic peptide with Actinobacillus actinomycetemcomitans. J Periodontal Res 37:416424.[ISI][Medline]
Lu Z, Murray KS, Van Cleave V, LaVallie ER, Stahl ML, McCoy JM (1995). Expression of thioredoxin random peptide libraries on the Escherichia coli cell surface as functional fusions to flagellin: a system designed for exploring protein-protein interactions. Biotechnology 13:366372.[Medline]
Marcotte H, Lavoie MC (1998). Oral microbial ecology and the role of salivary immunoglobulin A. Microbiol Mol Biol Rev 62:71109.
Murthy KK, Shen SH, Banville D (1998). Epitope mapping of SHP-1 monoclonal antibodies using peptide phage display. Biochem Biophys Res Commun 248:6974.[ISI][Medline]
Pasqualini R, Koivunen E, Ruoslahti E (1995). A peptide isolated from phage display libraries is a structural and functional mimic of an RGD-binding site on integrins. J Cell Biol 130:11891196.
Philippe B, Brion JP, Macq AF, Octave JN (1993). A new monoclonal antibody against the anionic domain of the amyloid precursor protein of Alzheimers disease. Neuroreport 5:289292.[ISI][Medline]
Rundegren JL, Arnold RR (1987). Bacteria-agglutinating characteristics of secretory IgA and a salivary agglutinin. Adv Exp Med Biol 216(B):10051013.
Rykke M, Sonju T, Rølla G (1990). Interindividual and longitudinal studies of amino acid composition of pellicle collected in vivo. Scand J Dent Res 98:129134.[ISI][Medline]
Samuelson P, Gunneriusson E, Nygren PA, Stahl S (2002). Display of proteins on bacteria. J Biotechnol 96:129154.[ISI][Medline]
Scannapieco FA (1994). Saliva-bacterium interactions in oral microbial ecology. Crit Rev Oral Biol Med 5:203248.
Scott JK, Smith GP (1990). Searching for peptide ligands with an epitope library. Science 249:386390.
Sibille P, Strosberg AD (1997). A FIV epitope defined by a phage peptide library screened with a monoclonal anti-FIV antibody. Immunol Lett 59:133137.[ISI][Medline]
Soares RV, Liu B, Oppenheim FG, Offner GD, Troxler RF (2002). Structural characterisation of cysteines in a bacterial-binding motif of human salivary mucin MG2. Arch Oral Biol 47:591597.[ISI][Medline]
Tabak LA, Levine MJ, Jain NK, Bryan AR, Cohen RE, Monte LD, et al. (1985). Adsorption of human salivary mucins to hydroxyapatite. Arch Oral Biol 30:423427.[ISI][Medline]
Weinberg ED (2001). Human lactoferrin: a novel therapeutic with broad spectrum potential. J Pharm Pharmacol 53:13031310.[ISI][Medline]
Woodward MP, Young WW Jr, Bloodgood RA (1985). Detection of monoclonal antibodies specific for carbohydrate epitopes using periodate oxidation. J Immunol Methods 78:143153.[ISI][Medline]
Yao Y, Grogan J, Zehnder M, Lendenmann U, Nam B, Wu Z, et al. (2001). Compositional analysis of human acquired enamel pellicle by mass spectrometry. Arch Oral Biol 46:293303.[ISI][Medline]
This article has been cited by other articles:
![]() |
E.J. Helmerhorst and F.G. Oppenheim Saliva: a Dynamic Proteome J. Dent. Res., August 1, 2007; 86(8): 680 - 693. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Ge, D. M. Catt, and R. L. Gregory Streptococcus mutans Surface {alpha}-Enolase Binds Salivary Mucin MG2 and Human Plasminogen Infect. Immun., November 1, 2004; 72(11): 6748 - 6752. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| IADR Journals | Advances in Dental Research ® |
| Journal of Dental Research ® | Critical Reviews (1990-2004) |